Nicole L De La Mata1, Nagalingeswaran Kumarasamy2, Vohith Khol3, Oon Tek Ng4, Kinh Van Nguyen5, Tuti Parwati Merati6, Thuy Thanh Pham7, Man Po Lee8, Nicolas Durier9, Matthew Law1. 1. The Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 2. Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), YRGCARE Medical Centre, VHS, Chennai, India. 3. National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. 4. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore. 5. National Hospital for Tropical Diseases, Hanoi, Vietnam. 6. Department of Internal Medicine, Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia. 7. Bach Mai Hospital, Hanoi, Vietnam. 8. Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China. 9. TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
BACKGROUND: Antiretroviral treatment (ART) for HIV-positive patients has expanded rapidly in Asia over the last 10 years. Our study aimed to describe the time trends and risk factors for overall survival in patients receiving first-line ART in Asia. METHODS: We included HIV-positive adult patients who initiated ART between 2003-2013 (n=16,546), from seven sites across six Asia-Pacific countries. Patient follow-up was to May 2014. We compared survival for each country and overall by time period of ART initiation using Kaplan-Meier curves. Factors associated with mortality were assessed using Cox regression, stratified by site. We also summarized first-line ART regimens, CD4+ T-cell count at ART initiation, and CD4+ T-cell and HIV viral load testing frequencies. RESULTS: There were 880 deaths observed over 54,532 person-years of follow-up, a crude rate of 1.61 (95% CI 1.51, 1.72) per 100 person-years. Survival significantly improved in more recent years of ART initiation. The survival probability at 4 years follow-up for those initiating ART in 2003-2005 was 92.1%, 2006-2009 was 94.3% and 2010-2013 was 94.5% (P<0.001). Factors associated with higher mortality risk included initiating ART in earlier time periods, older age, male sex, injecting drug use as HIV exposure and lower pre-ART CD4+ T-cell count. Concurrent with improved survival was increased tenofovir use, ART initiation at higher CD4+ T-cell counts and greater monitoring of CD4+ T-cells and HIV viral load. CONCLUSIONS: Our results suggest that HIV-positive patients from Asia have improved survival in more recent years of ART initiation. This is likely a consequence of improvements in treatment, patient management and monitoring over time.
BACKGROUND: Antiretroviral treatment (ART) for HIV-positive patients has expanded rapidly in Asia over the last 10 years. Our study aimed to describe the time trends and risk factors for overall survival in patients receiving first-line ART in Asia. METHODS: We included HIV-positive adult patients who initiated ART between 2003-2013 (n=16,546), from seven sites across six Asia-Pacific countries. Patient follow-up was to May 2014. We compared survival for each country and overall by time period of ART initiation using Kaplan-Meier curves. Factors associated with mortality were assessed using Cox regression, stratified by site. We also summarized first-line ART regimens, CD4+ T-cell count at ART initiation, and CD4+ T-cell and HIV viral load testing frequencies. RESULTS: There were 880 deaths observed over 54,532 person-years of follow-up, a crude rate of 1.61 (95% CI 1.51, 1.72) per 100 person-years. Survival significantly improved in more recent years of ART initiation. The survival probability at 4 years follow-up for those initiating ART in 2003-2005 was 92.1%, 2006-2009 was 94.3% and 2010-2013 was 94.5% (P<0.001). Factors associated with higher mortality risk included initiating ART in earlier time periods, older age, male sex, injecting drug use as HIV exposure and lower pre-ARTCD4+ T-cell count. Concurrent with improved survival was increased tenofovir use, ART initiation at higher CD4+ T-cell counts and greater monitoring of CD4+ T-cells and HIV viral load. CONCLUSIONS: Our results suggest that HIV-positive patients from Asia have improved survival in more recent years of ART initiation. This is likely a consequence of improvements in treatment, patient management and monitoring over time.
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Johan van Griensven; Rony Zachariah; Freya Rasschaert; Jules Mugabo; Edi F Atté; Tony Reid Journal: Trans R Soc Trop Med Hyg Date: 2009-09-03 Impact factor: 2.184
Authors: Andrew Boulle; Catherine Orrel; Richard Kaplan; Gilles Van Cutsem; Matthew McNally; Katherine Hilderbrand; London Myer; Matthias Egger; David Coetzee; Gary Maartens; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy Journal: Int J STD AIDS Date: 2017-03-21 Impact factor: 1.359
Authors: Rainer Puhr; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Rimke Bijker; Sasisopin Kiertiburanakul; Nagalingeswaran Kumarasamy; Sanjay Pujari; Ly P Sun; Oon T Ng; Man P Lee; Jun Y Choi; Kinh V Nguyen; Yu J Chan; Tuti P Merati; Do D Cuong; Jeremy Ross; Awachana Jiamsakul Journal: Antivir Ther Date: 2020
Authors: Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Man Po Lee; Cuong Duy Do; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: AIDS Care Date: 2017-01-29
Authors: Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng Journal: Antivir Ther Date: 2018
Authors: Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: R Bijker; N Kumarasamy; S Kiertiburanakul; S Pujari; L Penh Sun; O T Ng; M P Lee; J Y Choi; K V Nguyen; Y J Chan; T P Merati; C D Do; J Ross; M Law Journal: HIV Med Date: 2019-07-23 Impact factor: 3.180
Authors: W M Han; A Jiamsakul; J Jantarapakde; E Yunihastuti; J Y Choi; R Ditangco; R Chaiwarith; L P Sun; S Khusuwan; T P Merati; C D Do; I Azwa; M-P Lee; K Van Nguyen; Y-J Chan; S Kiertiburanakul; O T Ng; J Tanuma; S Pujari; F Zhang; Y M Gani; S Sangle; J Ross; N Kumarasamy Journal: HIV Med Date: 2020-11-17 Impact factor: 3.180